Current market landscape with a focus on prescription drugs and the future potential of this evolving market

Dublin, July 20, 2021 (GLOBE NEWSWIRE) – The “Non-hormonal therapies for women’s health market by target indication, molecule type, goal of treatment, mechanism of action, route of administration, and key geographies: Industry trends and global forecast, 2021-2030 “ report was added to offer.

The ‘Non-Hormonal Therapies for Women’s Health Market 2021-2030’ report presents an in-depth study of the current landscape of the non-hormonal therapies market, primarily focusing on prescription drugs. The study also includes an in-depth discussion about the future potential of this evolving market.

One of the main objectives of the report was to estimate the size of the existing market, and future opportunities associated with non-hormonal therapies, over the next decade. Based on several parameters, such as target patient population, likely adoption rates, and expected prices, we have provided educated estimates on how the market will develop for the period 2021-2030.

In recent years, the development and introduction of non-hormonal alternatives has revolutionized women’s health care. Brisdelle was the first of these products, approved in 2013 for the management of hot flashes in postmenopausal women. To date, 21 non-hormonal therapies (recent examples include OriahnnT, PhexxiT, and Esmya) have been approved. In addition, several of these non-hormonal product candidates are being evaluated at various stages of product development.

The inherent advantages of non-hormonal therapies, such as an improved safety profile, the ability to maintain hormonal balance, and relatively short treatments, compared to their hormonal counterparts have been demonstrated in both clinical trials and clinical trials. post-approval studies of the product. As a result, these products are currently preferred over hormonal therapies, and the pipeline of non-hormonal therapies is expected to continue to grow steadily over the next few years.

It should be noted that significant partnership activity has been observed in this market, with several stakeholders entering into strategic collaborations to support ongoing product development and commercialization initiatives. For the foreseeable future, the promising results of ongoing clinical research initiatives should lead to further investment to support product development activities in this upcoming market segment. We are therefore led to anticipate significant growth in this area in the years to come.

Scope of the report

Among other elements, the report includes:

  • A detailed examination of the overall landscape of the non-hormonal therapies market, including information on their current stage of development (commercialization, clinical, preclinical and discovery), molecule type (biological and small molecule), target indication (vaginosis) bacterial, contraception, endometriosis, postmenopausal osteoporosis, uterine fibroids, vaginitis and others), goal of treatment (disease treatment and symptom management), target population of women (adults, postmenopausal and premenopausal women, postmenopausal women), mechanism of action (antagonists, agonists, inhibitors and modulators), route of administration (intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal and others) and assigned special drug designation (s) (if applicable).

  • A detailed examination of the players engaged in the development of non-hormonal therapies, as well as information on their year of establishment, size of the company, location of the head office and the regional landscape.

  • An in-depth discussion of the different marketing strategies that can be adopted by drug developers engaged in this field, at different stages of therapy development, including pre-drug launch, during / at drug launch, and post-market of the drug.

  • Detailed profiles of phase III non-hormonal therapies. Each drug profile presents a brief overview of the therapy, along with information on their current state of development, route of administration, primary target indication, dosage, mechanism of action, clinical trials, results. clinical trials, collaborations and special drug designations received. (if only).

  • A detailed geographic analysis of clinical trials of completed and ongoing studies of non-hormonal therapies, based on several relevant parameters, such as year of trial registration, trial status, phase of the trial, target indication, geography, type of sponsor, major treatment sites and patient enrolled population.

  • An analysis of the various partnerships that have been signed by stakeholders engaged in the development of non-hormonal therapies, during the period before 2013-2020, including research agreements, research and development agreements, manufacturing agreements under contract, license agreements and other types of relevant agreements. It also presents a detailed analysis of the investments made, including award / grant, seed finance, venture capital finance, debt finance and others, in companies active in this field.

Answers to key questions

  • Who are the main industry players engaged in the development of non-hormonal therapies?

  • How many candidates for non-hormonal therapy make up the current development pipeline? What indications of diseases related to women’s health are targeted by these products?

  • What marketing strategies are most often adopted by developers of non-hormonal therapies at different stages of product development?

  • What partnership models are commonly adopted by the actors involved in this field?

  • What are the main value drivers of M&A activity in the non-hormonal therapies industry?

  • Who are the main stakeholders who have actively invested in the field of non-hormonal therapies?

  • How are current and future market opportunities likely to be distributed among key market segments?

Companies mentioned

  • AbbVie

  • Actavis

  • Adjuvant capital

  • Capital of Aisling

  • Allergan

  • Amgen

  • Amplity Health

  • Arcadia Securities

  • Aspire Capital Fund

  • Astellas Pharma

  • Avomeen

  • Azur Biotech

  • Bayer

  • BB Biotech

  • Boehringer Ingelheim

  • Broadfin Capital

  • Brookline Capital Markets

  • Cantor Fitzgerald

  • Ceek Women’s Health

  • Celmatix

  • Chugai Pharmaceutical

  • Therapeutic Cidara

  • DAFNA capital management

  • Dare the biosciences

  • Duchesnay

  • Eli lilly

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

  • Evofem Biosciences

  • Evotec

  • Exeltis

  • Ferring Pharmaceuticals

  • First Manhattan Co.

  • Forestry laboratories

  • Pharmaceuticals Fougera

  • Gédéa Biotech

  • Gideon Richter

  • Ghost tree capital

  • Grand Point Partners

  • Guggenheim titles

  • HC Wainwright & Co.

  • Hammock Pharmaceuticals (acquired by Element Nutritional Sciences)

  • Hansoh Pharma

  • Health decisions

  • Hennepin Life Sciences

  • Inmunotek

  • Inovio Pharmaceuticals

  • Intralytix, the Eliava Foundation

  • ITF Pharma

  • Jiangsu Hengrui Medicine

  • KaNDy Therapeutics (acquired by Bayer)

  • Kindeva drug delivery

  • Kissei Pharmaceutical

  • Korean Investment Partners (KIP)

  • Ladenbourg Thalmann

  • Pharmaceutical Ligand

  • Pharmaceutical Lupine

  • Medtech4Health

  • Merck Sharp & Dohme

  • Milan pharmacy

  • Mitsubishi Tanabe Pharma

  • Medical Research Commercialization Fund (MRCF)

  • Mycovie Pharmaceutical

  • Myovant Sciences

  • National participations

  • National Securities Company

  • Neurocrine biosciences

  • New business associates

  • New Leaf Venture Partners

  • NovaDigm Therapeutics

  • Novartis Pharma

  • Noven Pharmaceuticals

  • ObsEva

  • Ogeda

  • Omega Fund

  • Oxford Finances

  • PDL BioPharma

  • Pfizer

  • Prosight capital

  • Capital Power

  • THAT Oncology

  • Department health

  • Repros Therapeutics (acquired by Allergan)

  • rock

  • Sanofi Aventis


  • Shionogi

  • Sofinnova companies

  • Sphera Global Healthcare Fund

  • Square bank 1

  • Starpharma

  • Strategic science and technology

  • Sumitomo Dainippon Pharma

  • Swelife

  • Symbiomix Therapeutics (acquired by Lupine)

  • Pharmaceutical Takeda

  • TriLogic Pharma

  • Uniseed

  • Venrock Healthcare Capital Partners

  • Financing Vinnova

  • Vinnova grants

  • WBB titles

  • Woodford Investment Management

  • Xanodyne Pharmaceuticals

  • Yaso Therapeutics

Non-Hormonal Therapies for the Women’s Health Market: Sales Forecast by Product

  • NuvessaT (Metronidazole)

  • VivaGelT (SPL 7013)

  • SolosecT (Secnidazole)

  • TymlosT (Abaloparatide)

  • Orilissa

  • Osphena (Ospemifene)

  • EvenityT (Romosozumab-aqqg)

  • Esmya and Fibristal (ulipristal acetate)

  • PhexxiT (Amphora)

  • OriahnnT

  • Relugolix

  • DARE-BV1 (clindamycin gel)

  • Ovaprene

  • Yselty (Linzagolix)

  • Fezolinetant

  • BAY1002670 (Vilaprisan)

  • Abaloparatide-TD

  • Terconazole (0.4%)

  • SCY-078 (Ibrexafungerp)

  • VT-1161 (Oteseconazole)

  • MV140 (Uromune)

  • EVO100

For more information on this report, visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Source link

About Susan Dailey


Check Also

Women’s Basketball USA vs. Nigeria, Men’s Basketball USA vs. Spain

United States Women’s Basketball – 5:30 p.m. vs Nigeria at Michelob ULTRA Arena in Mandalay …

Leave a Reply

Your email address will not be published. Required fields are marked *